Prevalence and Clinical Severity of Autoimmune Blistering Diseases
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Gender/Age: Males or females above 18 years old
• Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid
• Subjects able to give informed consent
Locations
United States
Pennsylvania
Hospital of the University of Pennsylvania
RECRUITING
Philadelphia
Hospital of the University of Pennsylvania, Department of Dermatology
RECRUITING
Philadelphia
University of Pennsylvania, Department of Dermatology
RECRUITING
Philadelphia
Contact Information
Primary
Victoria P Werth, MD
werth@pennmedicine.upenn.edu
215-615-2940
Backup
Joyce Okawa, RN
Joyce.Okawa@pennmedicine.upenn.edu
215-615-2960
Time Frame
Start Date: 2016-04
Estimated Completion Date: 2030-01-02
Participants
Target number of participants: 150
Related Therapeutic Areas
Sponsors
Leads: University of Pennsylvania